Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why
02:39pm, Tuesday, 06'th Sep 2022 Zacks Investment Research
Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.
Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?
01:40pm, Tuesday, 06'th Sep 2022 Zacks Investment Research
Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.
Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?
11:17am, Tuesday, 06'th Sep 2022
Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.
Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?
04:00pm, Monday, 05'th Sep 2022 Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Monday, 05'th Sep 2022
Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
04:29pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
01:32pm, Friday, 02'nd Sep 2022
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
02:33pm, Thursday, 01'st Sep 2022 Benzinga
Upgrades
For iQIYI Inc (NASDAQ:IQ), UBS upgraded the previous rating of Neutral to Buy. For the second quarter, iQIYI had an EPS of $0.01, compared to year-ago quarter EPS of $0.27. At the moment, the
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%
01:55pm, Thursday, 01'st Sep 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is quest
Where Pliant Therapeutics Stands With Analysts
01:13pm, Thursday, 01'st Sep 2022 Benzinga
Analysts have provided the following ratings for Pliant Therapeutics (NASDAQ:PLRX) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%
11:34am, Thursday, 01'st Sep 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is quest
Pliant Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 30'th Aug 2022
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study
05:12pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
04:24pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
04:42pm, Tuesday, 23'rd Aug 2022 Zacks Investment Research
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
